Skip to main content
Erschienen in:

31.01.2022 | Original Article

Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group

verfasst von: Chalinee Monsereenusorn, Kunanya Suwannaying, Piti Techavichit, Lalita Sathitsamitphong, Patcharee Komvilaisak, Piya Rujkijyanont, Panya Seksarn, Pimlak Charoenkwan, Samart Pakakasama

Erschienen in: International Journal of Hematology | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease across all age groups and is characterized by various degrees of severity and organ system involvement. A multi-institutional retrospective study of pediatric patients with LCH treated between 1999 and 2018 at five pediatric oncology centers was conducted to describe the clinical characteristics, prognostic factors, and outcomes of LCH and to validate screening tools for organ system involvement in pediatric LCH in Thailand. A total of 127 patients with a median age of 2.7 years were studied. The single-to-multisystem (MS) LCH ratio was 1:1. Forty-seven patients (71%) with MS-LCH had risk-organ involvement (RO +), whereas 19 (29%) patients had no risk-organ involvement (RO −). The 5-year overall and event-free survival rates were 91.3% and 73.6%, respectively, which were comparable to those in developed countries. Prognostic factors included age < 2 years, RO + MS-LCH, and number of RO + . Abnormal complete blood count was a highly sensitive indicator of bone marrow involvement. Plain radiography is an appropriate screening tool to detect bone involvement.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135:1319–31.CrossRef Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020;135:1319–31.CrossRef
2.
Zurück zum Zitat Ribeiro KB, Degar B, Antoneli CB, Rollins B, Rodriguez-Galindo C. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2015;62(6):982–7.CrossRef Ribeiro KB, Degar B, Antoneli CB, Rollins B, Rodriguez-Galindo C. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2015;62(6):982–7.CrossRef
3.
Zurück zum Zitat Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009;94(5):376–80.CrossRef Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009;94(5):376–80.CrossRef
4.
Zurück zum Zitat Monsereenusorn C, Rodriguez-Galindo C. Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin N Am. 2015;29(5):853–73.CrossRef Monsereenusorn C, Rodriguez-Galindo C. Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin N Am. 2015;29(5):853–73.CrossRef
5.
Zurück zum Zitat Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol. 2018;78(6):1047–56.CrossRef Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol. 2018;78(6):1047–56.CrossRef
6.
Zurück zum Zitat Su M, Gao YJ, Pan C, Chen J, Tang JY. Outcome of children with Langerhans cell histiocytosis and single-system involvement: a retrospective study at a single center in Shanghai. China Pediatr Hematol Oncol. 2018;35(7–8):385–92.CrossRef Su M, Gao YJ, Pan C, Chen J, Tang JY. Outcome of children with Langerhans cell histiocytosis and single-system involvement: a retrospective study at a single center in Shanghai. China Pediatr Hematol Oncol. 2018;35(7–8):385–92.CrossRef
7.
Zurück zum Zitat Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111(5):2556–62.CrossRef Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111(5):2556–62.CrossRef
8.
Zurück zum Zitat Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14.CrossRef Gadner H, Minkov M, Grois N, Potschger U, Thiem E, Arico M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121(25):5006–14.CrossRef
10.
Zurück zum Zitat Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 study group. Med Pediatr Oncol. 1994;23(2):72–80.CrossRef Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 study group. Med Pediatr Oncol. 1994;23(2):72–80.CrossRef
11.
Zurück zum Zitat Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000;212(4):139–44.CrossRef Minkov M, Grois N, Heitger A, Potschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000;212(4):139–44.CrossRef
12.
Zurück zum Zitat Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107(3):613–9.CrossRef Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107(3):613–9.CrossRef
13.
Zurück zum Zitat Imashuku S, Kinugawa N, Matsuzaki A, Kitoh T, Ohki K, Shioda Y, et al. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems. Int J Hematol. 2009;90(4):506–12.CrossRef Imashuku S, Kinugawa N, Matsuzaki A, Kitoh T, Ohki K, Shioda Y, et al. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems. Int J Hematol. 2009;90(4):506–12.CrossRef
14.
Zurück zum Zitat Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138(5):728–34.CrossRef Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr. 2001;138(5):728–34.CrossRef
15.
Zurück zum Zitat Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379(9):856–68.CrossRef Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018;379(9):856–68.CrossRef
16.
Zurück zum Zitat Monsereenusorn C, Minkov M, Rodriguez-Galindo C. Current treatment of Langerhans cell histiocytosis. Expert Opin Orphan Drugs. 2016;4(10):1057–68.CrossRef Monsereenusorn C, Minkov M, Rodriguez-Galindo C. Current treatment of Langerhans cell histiocytosis. Expert Opin Orphan Drugs. 2016;4(10):1057–68.CrossRef
17.
Zurück zum Zitat Reisi N, Raeissi P, Harati Khalilabad T, Moafi A. Unusual sites of bone involvement in Langerhans cell histiocytosis: a systematic review of the literature. Orphanet J Rare Dis. 2021;16(1):1.CrossRef Reisi N, Raeissi P, Harati Khalilabad T, Moafi A. Unusual sites of bone involvement in Langerhans cell histiocytosis: a systematic review of the literature. Orphanet J Rare Dis. 2021;16(1):1.CrossRef
18.
Zurück zum Zitat Donadieu J, Rolon MA, Thomas C, Brugieres L, Plantaz D, Emile JF, et al. Endocrine involvement in pediatric-onset Langerhans’ cell histiocytosis: a population-based study. J Pediatr. 2004;144(3):344–50.CrossRef Donadieu J, Rolon MA, Thomas C, Brugieres L, Plantaz D, Emile JF, et al. Endocrine involvement in pediatric-onset Langerhans’ cell histiocytosis: a population-based study. J Pediatr. 2004;144(3):344–50.CrossRef
19.
Zurück zum Zitat Kim JR, Yoon HM, Jung AY, Cho YA, Seo JJ, Lee JS. Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis. Sci Rep. 2019;9(1):317.CrossRef Kim JR, Yoon HM, Jung AY, Cho YA, Seo JJ, Lee JS. Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis. Sci Rep. 2019;9(1):317.CrossRef
20.
Zurück zum Zitat Zhao M, Tang L, Sun S, Cui J, Chen H. Radiologic findings that aid in the reduction of misdiagnoses of Langerhans cell histiocytosis of the bone: a retrospective study. World J Surg Oncol. 2021;19(1):146.CrossRef Zhao M, Tang L, Sun S, Cui J, Chen H. Radiologic findings that aid in the reduction of misdiagnoses of Langerhans cell histiocytosis of the bone: a retrospective study. World J Surg Oncol. 2021;19(1):146.CrossRef
21.
Zurück zum Zitat Poompuen S, Chaiyarit J, Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study. Eur J Pediatr. 2019;178(5):771–6.CrossRef Poompuen S, Chaiyarit J, Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study. Eur J Pediatr. 2019;178(5):771–6.CrossRef
22.
Zurück zum Zitat Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006;46(1):66–71.CrossRef Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer. 2006;46(1):66–71.CrossRef
23.
Zurück zum Zitat Kim HK, Park CJ, Jang S, Cho YU, Park SH, Koh KN, et al. Bone marrow involvement of Langerhans cell histiocytosis: immunohistochemical evaluation of bone marrow for CD1a, Langerin, and S100 expression. Histopathology. 2014;65(6):742–8.CrossRef Kim HK, Park CJ, Jang S, Cho YU, Park SH, Koh KN, et al. Bone marrow involvement of Langerhans cell histiocytosis: immunohistochemical evaluation of bone marrow for CD1a, Langerin, and S100 expression. Histopathology. 2014;65(6):742–8.CrossRef
24.
Zurück zum Zitat Haupt R, Minkov M, Astigarraga I, Schafer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175–84.CrossRef Haupt R, Minkov M, Astigarraga I, Schafer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175–84.CrossRef
25.
Zurück zum Zitat Guo Y, Ning F, Wang G, Li X, Liu J, Yuan Y, et al. Retrospective study of Langerhans cell histiocytosis in ear, nose and neck. Am J Otolaryngol. 2020;41(2): 102369.CrossRef Guo Y, Ning F, Wang G, Li X, Liu J, Yuan Y, et al. Retrospective study of Langerhans cell histiocytosis in ear, nose and neck. Am J Otolaryngol. 2020;41(2): 102369.CrossRef
26.
Zurück zum Zitat Gao YJ, Su M, Tang JY, Pan C, Chen J. Treatment outcome of children with multisystem langerhans cell histiocytosis: the experience of a single children’s hospital in Shanghai. China J Pediatr Hematol Oncol. 2018;40(1):e9–12.CrossRef Gao YJ, Su M, Tang JY, Pan C, Chen J. Treatment outcome of children with multisystem langerhans cell histiocytosis: the experience of a single children’s hospital in Shanghai. China J Pediatr Hematol Oncol. 2018;40(1):e9–12.CrossRef
27.
Zurück zum Zitat Kitticharoenjit P, Supakul N, Rujkijyanont P, Traivaree C, Photia A, Monsereenusorn C. Clinical characteristics and outcomes of Langerhans cell histiocytosis at a single institution in Thailand: a 20-year retrospective study. Asian Biomed. 2021;15(4):171–81.CrossRef Kitticharoenjit P, Supakul N, Rujkijyanont P, Traivaree C, Photia A, Monsereenusorn C. Clinical characteristics and outcomes of Langerhans cell histiocytosis at a single institution in Thailand: a 20-year retrospective study. Asian Biomed. 2021;15(4):171–81.CrossRef
28.
Zurück zum Zitat Braier JL, Rosso D, Latella A, Chantada G, Ozuna B, Ripoli M, et al. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with “risk-organ” multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2010;32(4):e122–5.CrossRef Braier JL, Rosso D, Latella A, Chantada G, Ozuna B, Ripoli M, et al. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with “risk-organ” multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2010;32(4):e122–5.CrossRef
29.
Zurück zum Zitat Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, Japan LCHSG. Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies. Br J Haematol. 2021;192(3):615–20.CrossRef Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, Japan LCHSG. Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies. Br J Haematol. 2021;192(3):615–20.CrossRef
30.
Zurück zum Zitat Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the histiocyte society-late effects study group. Pediatr Blood Cancer. 2004;42(5):438–44.CrossRef Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the histiocyte society-late effects study group. Pediatr Blood Cancer. 2004;42(5):438–44.CrossRef
31.
Zurück zum Zitat Wnorowski M, Prosch H, Prayer D, Janssen G, Gadner H, Grois N. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr. 2008;153(1):127–32.CrossRef Wnorowski M, Prosch H, Prayer D, Janssen G, Gadner H, Grois N. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr. 2008;153(1):127–32.CrossRef
32.
Zurück zum Zitat Monsereenusorn C, Friedrich P, Alcasabas P, Lam C, Rodriguez-Galindo C, editors. Burden of pediatric solid tumors management in South-East Asia Countries. In: Presented at the 49th annual congress of the international society of paediatric oncology, Washington DC, USA, October 12–15, 2017. Monsereenusorn C, Friedrich P, Alcasabas P, Lam C, Rodriguez-Galindo C, editors. Burden of pediatric solid tumors management in South-East Asia Countries. In: Presented at the 49th annual congress of the international society of paediatric oncology, Washington DC, USA, October 12–15, 2017.
33.
Zurück zum Zitat Wang DS, Lu MY, Yang YL, Lin DT, Lin KH, Chang HH, et al. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: a single-center, 20-year experience. J Formos Med Assoc. 2021;120(1 Pt 3):594–601.CrossRef Wang DS, Lu MY, Yang YL, Lin DT, Lin KH, Chang HH, et al. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: a single-center, 20-year experience. J Formos Med Assoc. 2021;120(1 Pt 3):594–601.CrossRef
34.
Zurück zum Zitat Lee JW, Shin HY, Kang HJ, Kim H, Park JD, Park KD, et al. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years’ experience of 154 patients at a single center. Pediatr Hematol Oncol. 2014;31(3):293–302.CrossRef Lee JW, Shin HY, Kang HJ, Kim H, Park JD, Park KD, et al. Clinical characteristics and treatment outcome of Langerhans cell histiocytosis: 22 years’ experience of 154 patients at a single center. Pediatr Hematol Oncol. 2014;31(3):293–302.CrossRef
35.
Zurück zum Zitat Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, et al. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2018;108(2):192–8.CrossRef Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, et al. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2018;108(2):192–8.CrossRef
36.
Zurück zum Zitat Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887–98.CrossRef Rigaud C, Barkaoui MA, Thomas C, Bertrand Y, Lambilliotte A, Miron J, et al. Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age. Br J Haematol. 2016;174(6):887–98.CrossRef
37.
Zurück zum Zitat Othman MY, Blair S, Nah SA, Ariffin H, Assanasen C, Soh SY, et al. Pediatric solid tumor care and multidisciplinary tumor boards in low- and middle-income countries in Southeast Asia. JCO Glob Oncol. 2020;6:1328–45.CrossRef Othman MY, Blair S, Nah SA, Ariffin H, Assanasen C, Soh SY, et al. Pediatric solid tumor care and multidisciplinary tumor boards in low- and middle-income countries in Southeast Asia. JCO Glob Oncol. 2020;6:1328–45.CrossRef
38.
Zurück zum Zitat Narula G, Pradhan ND, Arora B, Banavali SD. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India. Pediatr Blood Cancer. 2018;65(8): e27028.CrossRef Narula G, Pradhan ND, Arora B, Banavali SD. Treatment of Langerhans cell histiocytosis with a modified risk-adapted protocol-experience from a tertiary cancer institute in India. Pediatr Blood Cancer. 2018;65(8): e27028.CrossRef
Metadaten
Titel
Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group
verfasst von
Chalinee Monsereenusorn
Kunanya Suwannaying
Piti Techavichit
Lalita Sathitsamitphong
Patcharee Komvilaisak
Piya Rujkijyanont
Panya Seksarn
Pimlak Charoenkwan
Samart Pakakasama
Publikationsdatum
31.01.2022
Verlag
Springer Singapore
Erschienen in
International Journal of Hematology / Ausgabe 4/2022
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-022-03293-0

Neu im Fachgebiet Onkologie

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Kein (großer) Schutz vor Kolorektalkarzinom-Rezidiven durch ASS

Die erste Phase-3-Studie zum Nutzen von ASS in der adjuvanten Therapie des kolorektalen Karzinoms ist negativ verlaufen. Das abschließende Urteil über eine Sekundärprävention mit ASS ist trotzdem noch nicht gefallen.

Frühe CLL-Therapie: BTK-Hemmer verlängert EFS und PFS, aber nicht OS

Auch nach sechs Jahren ergibt sich kein Überlebensvorteil einer Therapie mit dem BTK-Hemmer Ibrutinib für Menschen mit frühem CLL-Stadium und erhöhtem Progressionsrisiko. Die Progressionsrate wird mit der Behandlung jedoch um über 80% gesenkt.

Adjuvantes Atezolizumab ohne Nutzen bei frühem TNBC

Patientinnen mit frühem triple-negativem Brustkrebs profitieren nach der Operation offenbar nicht von einer Zugabe des PD-L1-Hemmers Atezolizumab zur adjuvanten Standardchemotherapie. Die Studie, die das untersucht hat, wurde vorzeitig abgebrochen. Was könnte die schlechte Wirksamkeit erklären?

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.